TRAW — Traws Pharma, Inc.

Summary of Traws Pharma, Inc. Q2 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of June 30, 2025, Traws had approximately $13.1 million in cash, cash equivalents, and short-term investments, down from $21.3 million at the end of 2024.
• Revenue: The company reported revenue of $2.7 million for Q2 2025, a significant increase from $57,000 in Q2 2024, primarily due to recognized deferred revenue from a terminated licensing agreement.
• Expenses:
  • R&D expenses decreased to $2.3 million from $4 million year-over-year, reflecting reduced oncology program costs.
  • General and administrative expenses fell to $1.7 million from $2 million, driven by lower personnel costs.
• Net Loss: The net loss for Q2 2025 was $0.9 million ($0.11 per share), a substantial improvement from a net loss of $123.1 million ($20.52 per share) in Q2 2024, which included a significant noncash charge.

2. Strategic Updates and Business Highlights

• COVID Program: Traws is advancing ratutrelvir, a ritonavir-free antiviral candidate for COVID-19, into Phase II trials. The trials will evaluate its efficacy against PAXLOVID and its potential to prevent Long COVID.
• Influenza Program: The company is in discussions with BARDA regarding tivoxavir marboxil, aimed at inclusion in the national drug stockpile for influenza, particularly bird flu. However, the initiation of related studies has been deferred due to low current infection rates.
• Oncology Assets: Traws is seeking partnerships to advance its legacy oncology drugs, rigosertib and narazaciclib, with promising efficacy data reported for rigosertib in a rare disease.

3. Forward Guidance and Outlook

• Traws expects to report results from the Phase II studies of ratutrelvir by year-end 2025, aiming to capture a significant market opportunity in the COVID-19 treatment space.
• The company is positioning tivoxavir marboxil for potential stockpiling as a preparedness measure against future influenza outbreaks.

4. Bad News, Challenges, or Points of Concern

• Regulatory Challenges: The FDA has indicated that clinical trial data will be necessary for regulatory approval of bird flu therapeutics, complicating Traws' development strategy.
• Market Conditions: The current low incidence of bird flu in the U.S. poses challenges for recruiting subjects for clinical trials, delaying potential advancements in the influenza program.
• Cash Burn: Despite improved financial metrics, the significant drop in cash reserves raises concerns about the company's financial sustainability and ability to fund ongoing operations and development.

5. Notable Q&A Insights

• The management team emphasized the urgency of developing effective treatments for COVID-19 and bird flu, citing the evolving nature of viral threats.
• There was a focus on the potential market for ratutrelvir, particularly among patients ineligible for PAXLOVID due to drug interactions.
• The discussion highlighted the importance of preparedness for future pandemics, reinforcing the strategic value of tivoxavir marboxil in Traws' portfolio.

Overall, Traws Pharma is making strategic moves to enhance its antiviral offerings while navigating regulatory and market challenges. The company is focused on improving its financial health and advancing its clinical programs to meet urgent public health needs.